A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2019
At a glance
- Drugs ABT 751 (Primary)
- Indications Neuroblastoma
- Focus Therapeutic Use
- 15 Oct 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 17 Jan 2012 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 17 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.